Skip to main content
SpringerLink
Log in

Depression After Myocardial Infarction

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Depression is an important disease state that requires significant time and resources to manage properly. The presence of depression in patients with cardiovascular disease has been strongly associated with detrimental effects in terms of morbidity and mortality. Although several large-scale and small studies have evaluated various interventions in the management of depression after myocardial infarction, a significant portion of these data have provided more questions than answers. Although limited, the randomized prospective clinical trial data evaluating interventions for the management of depression after myocardial infarction in patients with ischemic heart disease continue to produce promising findings for progressive and improved management of these devastating diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jiang W, Babyak MA, Rozanski A, et al.: Depression and increased myocardial ischemic activity in patients with ischemic heart disease. Am Heart J 2003, 146:55–61.

    Article  PubMed  Google Scholar 

  2. Jiang W, Krishnan RR, O’Connor CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002, 16:111–127.

    Article  PubMed  Google Scholar 

  3. Carney RM, Freedland KE, Jaffe AS, et al.: Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004, 44:472.

    Article  PubMed  Google Scholar 

  4. O’Connor CM, Jiang W, Kuchibhatla M, et al.: Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008, 168:2232–2237.

    Article  PubMed  Google Scholar 

  5. Pozuelo L, Tesar G, Zhang J, et al.: Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med 2009, 76:59–70.

    Article  PubMed  Google Scholar 

  6. Davidson KW, Burg MM, Kronish IM, et al.: Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry 2010, 67:480–488.

    Article  PubMed  Google Scholar 

  7. O’Connor CM, Glassman AH, Harrison DJ: Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005, 66:346–352.

    Article  PubMed  Google Scholar 

  8. Jiang W: Impacts of depression and emotional distress on cardiac disease. Cleve Clin J Med 2008, 75(Suppl 2):S20–S25.

    Article  PubMed  Google Scholar 

  9. Barefoot JC, Helms MJ, Mark DB, et al.: Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996, 78:613–617.

    Article  CAS  PubMed  Google Scholar 

  10. Bush DE, Ziegelstein RC, Tayback M, et al.: Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001, 88:337–341.

    Article  CAS  PubMed  Google Scholar 

  11. Jiang W, Krishnan RR: Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? Curr Psychiatry Rep 2004, 6:202–209.

    Article  PubMed  Google Scholar 

  12. • Lespérance F, Frasure-Smith N, Koszycki D, et al.: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007, 297:367–379. (Published erratum appears in JAMA 2007, 298:40.) The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy was a randomized, controlled, 12-week, parallel-group, 2 × 2 factorial trial among 284 patients with coronary artery disease from nine Canadian academic centers. There was no evidence of a benefit of interpersonal psychotherapy over clinical management, with the mean HAM-D difference favoring clinical management (–2.26 points; 96.7% CI, –4.78 to 0.27; P = 0.06; effect size, 0.23).

  13. Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 1998, 155:4–11.

    CAS  PubMed  Google Scholar 

  14. Barefoot JC, Schroll M: Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996, 93:1976–1980.

    CAS  PubMed  Google Scholar 

  15. Frasure-Smith N, Lespérance F, Gravel G, et al.: Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000, 48:471–478.

    Article  CAS  PubMed  Google Scholar 

  16. O’Connor CM, Joynt KE: Depression: are we ignoring an important comorbidity in heart failure? J Am Coll Cardiol 2004, 43:1550–1552.

    Article  PubMed  Google Scholar 

  17. O’Connor EA, Whitlock EP, Beil TL, Gaynes BN: Screening for depression in adult patients in primary care settings: a systematic evidence review. Ann Intern Med 2009, 151:793–803.

    PubMed  Google Scholar 

  18. Jiang W, Glassman A, Krishnan R, et al.: Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J 2005, 150:54–78.

    Article  PubMed  Google Scholar 

  19. Frasure-Smith N, Lespérance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation 1995, 91:999–1005. (Published erratum appears in Circulation 1998, 97:708.)

    Google Scholar 

  20. Lespérance F, Frasure-Smith N, Juneau M, Théroux P: Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000, 160:1354–1360.

    Article  PubMed  Google Scholar 

  21. Frasure-Smith N, Lespérance F, Gravel G, et al.: Long-term survival differences among low-anxious, high-anxious and repressive copers enrolled in the Montreal heart attack readjustment trial. Psychosom Med 2002, 64:571–579.

    Article  PubMed  Google Scholar 

  22. Jiang W, Davidson JR: Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005, 150:871–881.

    Article  CAS  PubMed  Google Scholar 

  23. Bigger JT Jr, Fleiss JL, Kleiger R, et al.: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984, 69:250–258.

    PubMed  Google Scholar 

  24. Greenberg HM, Dwyer EM Jr, Hochman JS, et al.: Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995, 74:631–635.

    Article  CAS  PubMed  Google Scholar 

  25. Glassman AH, Roose SP, Bigger JT Jr: The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993, 269:2673–2675.

    CAS  Google Scholar 

  26. Roose SP, Glassman AH, Giardina EG, et al.: Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987, 7:247–251.

    Article  CAS  PubMed  Google Scholar 

  27. Roose SP, Glassman AH, Giardina EG, et al.: Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986, 256:3253–3257.

    Article  CAS  PubMed  Google Scholar 

  28. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.

    Article  CAS  PubMed  Google Scholar 

  29. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992, 327:227–233.

    Article  Google Scholar 

  30. Shapiro PA: Treatment of depression in patients with congestive heart failure. Heart Fail Rev 2009, 14:7–12.

    Article  PubMed  Google Scholar 

  31. Jiang W, Blumenthal JA: Depression and ischemic heart disease: overview of the evidence and treatment implications. Curr Psychiatry Rep 2003, 5:47–54.

    Article  CAS  PubMed  Google Scholar 

  32. Watson K, Summers KM: Depression in patients with heart failure: clinical implications and management. Pharmacotherapy 2009, 29:49–63.

    Article  CAS  PubMed  Google Scholar 

  33. Roose SP, Glassman AH, Attia E, et al.: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998, 155:660–665.

    CAS  PubMed  Google Scholar 

  34. Rutledge T, Reis VA, Linke SE, et al.: Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006, 48:1527–1537.

    Article  PubMed  Google Scholar 

  35. Frasure-Smith N, Lespérance F, Prince RH, et al.: Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet 1997, 350:473–479.

    Article  CAS  PubMed  Google Scholar 

  36. Kellner R, Uhlenhuth EH: The rating and self-rating of anxiety. Br J Psychiatry Suppl 1991, (12):15–22.

    PubMed  Google Scholar 

  37. Berkman LF, Blumenthal J, Burg M, et al.: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003, 289:3106–3116.

    Article  PubMed  Google Scholar 

  38. Glassman AH, O’Connor CM, Califf RM, et al.: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701–709. (Published erratum appears in JAMA 2002, 288:1720.)

    Google Scholar 

  39. Serebruany VL, Glassman AH, Malinin AI, et al.: Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108:939–944. (Published erratum appears in Circulation 2003, 108:3165.)

    Google Scholar 

  40. Kotzailias N, Andonovski T, Dukic A, et al.: Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. J Clin Pharmacol 2006, 46:468–475.

    Article  CAS  PubMed  Google Scholar 

  41. •• Hansen BH, Hanash JA, Rasmussen A, et al.: Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials 2009, 10:20. The Depression in Acute Coronary Syndrome (DECARD) trial has been initiated to evaluate the use of the SSRI escitalopram in the possible prevention of depression in patients after ACS. The investigators of the published trial design seek to randomize 240 patients with ACS without depression to receive either escitalopram or placebo for 1 year to assess the rates of depression with preempted use of antidepressant therapy. The trial is still ongoing.

    PubMed  Google Scholar 

  42. •• Roncella A, Giornetti A, Cianfrocca C, et al.: Rationale and trial design of a randomized, controlled study on short-term psychotherapy after acute myocardial infarction: the STEP-IN-AMI trial (Short Term Psychotherapy in Acute Myocardial Infarction). J Cardiovasc Med (Hagerstown) 2009, 10:947–452. Short Term Psychotherapy in Acute Myocardial Infarction (STEP-IN-AMI) will assess the use of short-term cognitive behavioral therapy on clinical outcomes of patients who have undergone emergent PCI in the setting of acute MI. This study will provide insight into the use of short-term psychotherapy and how this intervention possibly affects clinical outcomes after interventional and medical treatment of AMI.

    Article  Google Scholar 

  43. Jiang W, Alexander J, Christopher E, et al.: Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001, 161:1849–1856.

    Article  CAS  PubMed  Google Scholar 

  44. Jiang W, Kuchibhatla M, Clary GL, et al.: Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007, 154:102–108.

    Article  PubMed  Google Scholar 

  45. Jiang W, Hasselblad V, Krishnan RR, O’Connor CM: Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression. J Am Coll Cardiol 2002, 39:919–921.

    Article  PubMed  Google Scholar 

  46. •• Jiang W, O'Connor C, Silva SG, et al.: Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J 2008, 156:437–444. The Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) is a prospective, randomized, double-blind, placebo-controlled trial that randomized a total of 469 heart failure patients with MDD to either sertraline (n = 234) or placebo (n = 235). At the end of the 12-week treatment, there were no significant differences in depression between patients receiving either sertraline or placebo. Even so, both groups had significant improvement in depression independently.

    Article  CAS  PubMed  Google Scholar 

  47. Mehra MR, Rockman HA, Greenberg BH: Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20–23, 2008. J Am Coll Cardiol 2009, 53:514–522.

    Article  PubMed  Google Scholar 

  48. •• Angermann CE, Gelbrich G, Stork S, et al.: Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007, 9:1212–1222. The Morbidity, Mortality and Mood in Depressed Heart Failure (MOOD-HF) study is an ongoing prospective, randomized, double-blind, multicenter trial investigating the efforts of the SSRI escitalopram on morbidity and mortality, severity of depression, anxiety, cognitive function, and quality of life in an estimated 700 patients. The primary end point for this analysis is time to first event of either death or unplanned hospitalization. The results of the primary analysis of MOOD-HF and subset studies hopefully will provide valuable confirmation for aggressive management of depression treatment in patients with heart failure.

    Article  CAS  PubMed  Google Scholar 

  49. Kennedy SH, Andersen HF, Thase ME: Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009, 25:161–175.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors of this review would like to thank Mona Fiuzat, PharmD, of the Duke Clinical Research Institute for her assistance in the preparation of this manuscript.

Disclosures

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Cardiology, Duke Cardiology of Lumberton, Duke University Medical Center, 2936 North Elm Street, Suite 102, Lumberton, NC, 28358, USA

    Melvin R. Echols

  2. Duke University Medical Center, PO Box 3356, Durham, NC, 27710, USA

    Christopher M. O’Connor

Authors
  1. Melvin R. Echols
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher M. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melvin R. Echols.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Echols, M.R., O’Connor, C.M. Depression After Myocardial Infarction. Curr Heart Fail Rep 7, 185–193 (2010). https://doi.org/10.1007/s11897-010-0024-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-010-0024-6

Keywords

Search

Navigation